Pre-treatment prediction of EBV‑DNA status in nasopharyngeal carcinoma using CE‑T1WI radiomics combined with clinical features: a multi‑sequence MRI radiomics study
We aimed to develop and validate an MRI radiomics‑based model for predicting EBV‑DNA status in NPC patients using a fully leakage‑free, nested validation framework.
Epstein‑Barr virus (EBV) DNA is a critical biomarker for nasopharyngeal carcinoma (NPC) diagnosis, treatment response, and prognosis. Noninvasive pre‑treatment prediction of EBV‑DNA status using magnetic resonance imaging (MRI) radiomics may provide additional clinical value. We aimed to develop and validate an MRI radiomics‑based model for predicting EBV‑DNA status in NPC patients using a fully leakage‑free, nested validation framework.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma